Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Ibuprofen in COVID-19
NCT04382768Unknown
- Sponsor
- Laboratorios Química Luar
- Start
- May 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of Luarprofen in COVID-19 pneumonia, sponsored by Laboratorios Química Luar. Primary endpoints: Change in the scale of ordinary COVID results at 28 days and Change to Negativization of the swab at 28 days. Status: unknown.
02
Drugs
Luarprofen
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04382768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04382768.